Industry Hosted Breakfast Symposium | Wednesday, 21 August 2019
Sanofi Hosted Breakfast
Hosted and supported by
Date: Wednesday, 21 August 2019
Time: 6:45am for 7:00am start – 8:00am
Room: C4.8
Title: The evolution of diabetes management
Chair: Professor Michael Horowitz (Adelaide)
Speaker/s: A/Prof Samantha Hocking, A/Prof Marg McGill
Cost: There is no cost to attend, however you must RSVP during the registration process
Agenda:
7:00-7:30am: Insulin optimisation in high risk type 2 patients (A/Prof Samantha Hocking)
7:30–8:00am: Panel discussion: Hot topics in diabetes care (A/Prof Samantha Hocking, A/Prof Marg McGill)
Medtronic Hosted Breakfast
Hosted and supported by
Date: Wednesday, 21 August 2019
Time: 6.45am for 7am start – 8am
Room: C4.11
Title: The Future of Patient Device Data and Carelink Reporting- Reducing Healthcare Professional Burden
Chair: To be confirmed
Speaker/s: Mr Brent Goldstein- Engineering Director, Connectivity Platforms Diabetes Global R&D, Medtronic
Cost: There is no cost to attend, however you must RSVP during the registration process
Summary: The audience will be taken through the current reports of patient diabetes device data. They will then be immersed in an interactive view of future look tools and dashboards designed to reduce HCP burden, but also quickly identify patients needing support between clinic appointments. They will also have the opportunity to provide direct input and feedback to the program designer.
Industry Hosted Breakfast Symposium | Thursday, 22 August 2019
Novo Nordisk Hosted Breakfast
Hosted and supported by
Date: Thursday, 22 August 2019
Time: 6.45am for 7am start – 8am
Room: C4.8
Title: Innovations and Advances in Diabetes Management
Chair: A/Prof Neale Cohen
Speaker/s: Prof Greg Fulcher, A/Prof Neale Cohen, A/Prof Jane Overland
Cost: There is no cost to attend, however you must RSVP during the registration process
Summary: A multitude of new treatments for the management of diabetes have emerged over the last decade. In the last year, Novo Nordisk Pharmaceuticals has launched two next-generation insulins; Fiasp® and Ryzodeg® 70/30, in Australia. This symposium will bring together a notable faculty of diabetes experts, who will discuss how beneficial these recent advancements in insulin are, and which patient groups may benefit from these. The faculty will also share their clinical experience with Fiasp® and Ryzodeg® 70/30 via the presentation of four case studies.
7:00-7:20 Benefits and Advances in Diabetes Management by Prof Greg Fulcher
7:20-7:50 Case Studies by Prof Greg Fulcher, A/Prof Neale Cohen, A/Prof Jane Overland
7:50-8:00 Question and Discussion Panel
Ypsomed Hosted Breakfast
Hosted and supported by
Date: Thursday, 22 August 2019
Time: 6.45am for 7am start – 8am
Room: C4.4
Title: How to support patients to choose the right therapy & technology decision. Real life Patient case studies from Western Health
Chair: To be confirmed
Speaker/s: Cheryl Steele RN – Clinical Nurse Consultant and Credentialled Diabetes Educator at Western Health Victoria
Cost: There is no cost to attend, however you must RSVP during the registration process
Summary: Cheryl will use a number of patient cases to discuss the role of the clinical team in supporting the patient’s own assessment and choice of technology & therapy solutions options that best suit them. Ultimately technology decisions rest with the patient. It is the role of the Clinical support team to present the available therapy and technology options in order to give the patient the ability to make an informed decision on the solution that best suits them. Not all patients are created equal and no one single therapy or technology solution fits all.
AstraZeneca Hosted Breakfast
Hosted and supported by
Date: Thursday, 22 August 2019
Time: 6.45am for 7am start – 8am
Room: C4.5
Title: The cardiorenal complications of type 2 diabetes
Chair: Professor Stephen Twigg, University of Sydney
Speaker/s: Professor Hiddo Lambers Heerspink, University of Groningen, Netherlands
Cost: There is no cost to attend, however you must RSVP during the registration process
Summary: Type 2 diabetes has a profound effect on the development of heart failure and is the leading cause of end-stage renal disease.
Heart failure and kidney disease overlap in many ways, including the haemodynamic interactions of the heart and kidney in HF, the impact of atherosclerotic disease across both organ systems, neurohormonal activation, cytokines, biochemical alterations in chronic kidney disease, and structural changes in the heart unique to chronic kidney disease progression. Type 2 diabetes can further increase these multifactorial mechanisms leading to greater risks for hospitalisation, morbidity, and death, as well as very high healthcare costs.
Please join us for an informative session to discuss the frequent, forgotten and often fatal complications of heart failure and chronic kidney disease in people with type 2 diabetes.
iNova Pharmaceuticals Hosted Breakfast
Hosted and supported by
Date: Thursday, 22 August 2019
Time: 6.45am for 7am start – 8am
Room: C4.3
Title: New pharmacological strategies to target obesity
Chair: Prof Colagiuri
Speaker/s: Professor Stephen Colagiuri, Professor of Metabolic Health and Director of The Boden Institute at The University of Sydney and Professor Michael Horowitz, Professor of Medicine and Head of Endocrine Unit at Royal Adelaide Hospital
Cost: There is no cost to attend, however you must RSVP during the registration process
Summary: This session will be two 25 minute presentations with 10 minutes for questions.
The first session will discuss key issues faced by endocrinologists when confronted by obesity in Australia. The Australian Obesity Treatment Algorithm and the Diabetes Management Algorithm will form the basis of a discussion centering around the current state of play in managing obesity. The importance of recognizing and treating obesity as a chronic disease to ensure best practice for patient outcomes will be highlighted, as will the implementation of various interventions (lifestyle, pharmacological and surgical).
The second session introduces a novel pharmacological strategy for the management of obesity in Australia. The mode of action, safety and efficacy of naltrexone and bupropion in managing obesity will be presented, with a focus on the clinical development program as well as the implications for this new therapy in the Australian obesity management landscape.